deltatrials
Completed PHASE2 INTERVENTIONAL NCT00063310

ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation

Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN)

Sponsor: Voyager Pharmaceutical Corporation

Conditions Alzheimer Disease
Interventions Leuprolide acetate
Updated 5 times since 2017 Last updated: Dec 10, 2009 Started: Mar 31, 2003 Primary completion: Feb 28, 2006 Completion: Feb 28, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Alzheimer Disease, this trial is completed. The trial is conducted by Voyager Pharmaceutical Corporation and has accumulated 5 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Voyager Pharmaceutical Corporation
Data source: National Institute on Aging (NIA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations